Virbac S.A.

Virbac is an independent veterinary pharmaceutical laboratory. Co. develops and provides veterinarians and farmers with medicines and vaccines that improve the health of food producing animals. Co. markets a range of products designed for pets and livestock. It offers seven types of products for companion animals (Parasiticides, Immunology, Antibiotics/dermatology, Specialties, Equine, Specialized pet food and Other products), and four types of products for food producing animals (Bovine parasiticides, Bovine products (excluding parasiticides), Pig/poultry antibiotics and Other products). Co. markets its products in the ethical (veterinarian) and OTC markets.
  • TickerVIRP
  • ISINFR0000031577
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Aurelien Sivignon ...
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • François Maury
  • Georges Dieng
  • Hela Zarrouk
  • Jean-François Granjon
  • Louis Boujard
  • Martial Descoutures
  • Nicolas David
  • Philippe Ourpatian
  • Pierre Corby
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 03/19/2019

...

Aurelien Sivignon ...
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • François Maury
  • Georges Dieng
  • Hela Zarrouk
  • Jean-François Granjon
  • Louis Boujard
  • Martial Descoutures
  • Nicolas David
  • Philippe Ourpatian
  • Pierre Corby
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 19/03/2019

...

Christophe-Raphaël Ganet

Virbac : 2018 results in line – Good cash management – Guidance in line with the consensus

>Earnings in line with guidance and the consensus - 2018 underlying operating profit totalled € 88.1m, i.e. 9.7%.Underlying operating profit totalled € 31.5m (+6.8%); it benefited from growth in activity and the fall in the cost of financing (deleveraging and a fall in interest rate effects compared with 2017 with the reduction in the share of US$ vs € denominated debt), but was penalised by an unfavourable forex impact (from the Chilean peso vis-à-vis the euro a...

Christophe-Raphaël Ganet

Virbac : Résultat 2018 en ligne – Bon cash management – Guidance en phase avec le consensus

>Résultat conforme aux guidances et au consensus - Le ROC 2018 se monte à 88,1 M€, en croissance de 9,7%.Le BN courant à 31,5 M€ (+6,8%) a bénéficié de la croissance de l’activité et de la baisse du coût de financement (désendettement et un effet baisse des taux d’intérêt comparé à 2017 avec la diminution de la part de la dette libellée en US$ vs €), mais il est pénalisé par un impact de change défavorable (du peso chilien vis-à-vis de l’euro et du dollar).L...

Aurelien Sivignon ...
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • François Maury
  • Georges Dieng
  • Hela Zarrouk
  • Jean-François Granjon
  • Louis Boujard
  • Martial Descoutures
  • Nicolas David
  • Philippe Ourpatian
  • Pierre Corby
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 03/19/2019

...

Aurelien Sivignon ...
  • Charles Lepetitpas
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • François Maury
  • Georges Dieng
  • Hela Zarrouk
  • Jean-François Granjon
  • Louis Boujard
  • Martial Descoutures
  • Nicolas David
  • Philippe Ourpatian
  • Pierre Corby
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 19/03/2019

...

Christophe-Raphaël Ganet

Virbac : 2018 results in line – Good cash management – Guidance in line with the consensus

>Earnings in line with guidance and the consensus - 2018 underlying operating profit totalled € 88.1m, i.e. 9.7%.Underlying operating profit totalled € 31.5m (+6.8%); it benefited from growth in activity and the fall in the cost of financing (deleveraging and a fall in interest rate effects compared with 2017 with the reduction in the share of US$ vs € denominated debt), but was penalised by an unfavourable forex impact (from the Chilean peso vis-à-vis the euro a...

Christophe-Raphaël Ganet

Virbac : Résultat 2018 en ligne – Bon cash management – Guidance en phase avec le consensus

>Résultat conforme aux guidances et au consensus - Le ROC 2018 se monte à 88,1 M€, en croissance de 9,7%.Le BN courant à 31,5 M€ (+6,8%) a bénéficié de la croissance de l’activité et de la baisse du coût de financement (désendettement et un effet baisse des taux d’intérêt comparé à 2017 avec la diminution de la part de la dette libellée en US$ vs €), mais il est pénalisé par un impact de change défavorable (du peso chilien vis-à-vis de l’euro et du dollar).L...

Christophe-Raphaël Ganet

Virbac : Q4 2018 sales: no real inflection - Neutral vs Buy – TP: € 138 vs € 147

>Q4 still shows fairly strong contrasts in the areas under surveillance - Q4 sales came in at € 234.5m, i.e. +1.2% and +1.8% at constant currencies (cc).Regarding species, pet sales rose by +3.9% overall, with +6.4% growth at constant currencies. In the livestock segment, overall growth stood at -3% with +2.2% at constant currencies (+5.7% excluding aquaculture).Latin America (excluding Chile) accounts for most of the growth (+5% and +15.5% at constant curre...

1 director bought

A director at Virbac bought 200 shares at 130.000EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members...

Aurelien Sivignon ...
  • Christophe-Raphaël Ganet
  • Jean-François Granjon
  • Jeremy Garnier
  • Johanna Jourdain
  • Laurence Hofmann
  • Nicolas Thorez
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 01/18/2019

...

Aurelien Sivignon ...
  • Christophe-Raphaël Ganet
  • Jean-François Granjon
  • Jeremy Garnier
  • Johanna Jourdain
  • Laurence Hofmann
  • Nicolas Thorez
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 18/01/2019

...

Alex Koagne ...
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Jean Sassus
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 10/15/2018

...

Ahmed Ben Salem ...
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Emira Sagaama
  • Jean Sassus
  • Laure Billoret
  • Matthias Desmarais
  • Steven Gould
  • Valentin Pernet
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/15/2018

...

Ahmed Ben Salem ...
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Emira Sagaama
  • Jean Sassus
  • Laure Billoret
  • Matthias Desmarais
  • Steven Gould
  • Valentin Pernet
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 15/10/2018

...

With a more favourable environment, VIRBAC improves to Positive

VIRBAC (FR), a company active in the Pharmaceuticals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date November 9, 2018, the closing price was EUR 147.40 and its potential was estimated at EUR 165.42.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

MarketLine Department

Zoetis Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Zoetis Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Zoetis Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlights ...

Jehanne Leroy

Etude de l'AG du 23/06/2017

Proxinvest regrette principalement le manque de transparence de la communication de la société concernant les rémunérations des dirigeants mandataires sociaux. C'est, en effet, en raison de ce manque de transparence que Proxinvest recommande de s'opposer aux résolutions 8 à 12, relatives aux rémunérations des dirigeants. Proxinvest regrette par ailleurs que la société maintienne la possibilité de l'usage de ces autorisations financières en période d'offre publique, en raison de leur possible utilisation comme arme anti-OPA. Proxinvest considère en effet que les OPA sont des opportunités d'enr...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Defensive posture warranted Our outlook for global equity markets remains cautious and we expect additional weakness and consolidation, notwithstanding shorter-term countertrend rallies. Indexes throughout Europe and Asia continue their struggle to gain a firm footing, and, unsurprisingly, the same can be said of broad developed and emerging market indexes (i.e., MSCI EAFE, EM, ACWI, ACWI ex-U.S.) which are all in downtrends or have recently broken down. In light of continued global market weakness, we believe a defensive posture is warranted. In today's report we highlight various ways to ac...

Valérie GASTALDY

Short term view - VIRBAC SA : The movement can go on.

The background trend is clearly bullish. The MACD is positive, it confirms that trend. The movement can go on. The following targets are at €152.70 and €157.00. The trend would be invalidated below the support at €138.60.

Valérie GASTALDY

Analyse court terme - VIRBAC SA : Le mouvement peut se poursuivre.

La tendance de fond est clairement orientée à la hausse. Le MACD est positif, il confirme cette tendance. Le mouvement peut se poursuivre. Les objectifs suivants sont à 152,70 € et 157,00 €. La tendance serait invalidée sous le support à 138,60 €.

Valérie GASTALDY

Short term view - VIRBAC SA : The background trend is clearly bullish.

The background trend is clearly bullish. The MACD is positive, it confirms that trend. The movement can go on. The following targets are at €152.70 and €157.00. The trend would be invalidated below the support at €138.60.

Valérie GASTALDY

Analyse court terme - VIRBAC SA : La tendance de fond est clairement orientée à la hausse.

La tendance de fond est clairement orientée à la hausse. Le MACD est positif, il confirme cette tendance. Le mouvement peut se poursuivre. Les objectifs suivants sont à 152,70 € et 157,00 €. La tendance serait invalidée sous le support à 138,60 €.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch